MedTrace Logo

Bevacizumab and Photodynamic Therapy in Neovascular Age Related Macular Degeneration

NCT00347399 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2024-05-30

No results posted yet for this study

Summary

The purpose of this study is to determine if of combination therapy of intravitreal bevacizumab 4 days after the application of photodynamic therapy could improve the visual outcomes of patients with neovascular age related macular degeneration.

Conditions

  • Age Related Macular Degeneration

Interventions

DRUG

bevacizumab intravitreal injection

PROCEDURE

verteporfin photodynamic therapy

Sponsors & Collaborators

  • Asociación para Evitar la Ceguera en México

    lead OTHER

Principal Investigators

  • Hugo Quiroz-Mercado, MD · Asociación para Evitar la Ceguera en México

  • Jose Dalma Weizhaus, MD · Asociación para Evitar la Ceguera en México

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
55 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2006-06-30
Completion
2007-06-30

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00347399 on ClinicalTrials.gov